Zikani’s unique proprietary platform (TURBO-ZM™) allows rapid synthesis of novel ribosome modulating agents (RMAs) that can be optimized to target the human ribosome in a disease-specific manner.Develop a clinical stage pipeline of treatments for rare diseases with a high unmet need, beginning with class 1 cystic fibrosis (CF), familial adenomatous polyposis (FAP), APC mutant colon cancer, and recessive dystrophic epidermo...
Zikani’s unique proprietary platform (TURBO-ZM™) allows rapid synthesis of novel ribosome modulating agents (RMAs) that can be optimized to target the human ribosome in a disease-specific manner.Develop a clinical stage pipeline of treatments for rare diseases with a high unmet need, beginning with class 1 cystic fibrosis (CF), familial adenomatous polyposis (FAP), APC mutant colon cancer, and recessive dystrophic epidermolysis bullosa (RDEB)
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.